MUSCLE & BACK PAIN RELIEF CAPLETS 325 MG
ACETAMINOPHEN : 325 MG METHOCARBAMOL : 400 MG · DIN 02230790 · VITA HEALTH PRODUCTS INC
Health Canada status: MARKETED
What is MUSCLE & BACK PAIN RELIEF CAPLETS?
MUSCLE & BACK PAIN RELIEF CAPLETS 325 MG contains ACETAMINOPHEN : 325 MG METHOCARBAMOL : 400 MG. It is listed in the Health Canada Drug Product Database under DIN 02230790, held by VITA HEALTH PRODUCTS INC, supplied as TABLET for ORAL administration. Health Canada currently lists it as marketed, status dated 17-Oct-2001. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
Product details and regulatory record
| DIN | 02230790 |
|---|---|
| Brand name | MUSCLE & BACK PAIN RELIEF CAPLETS |
| Generic / active ingredient | ACETAMINOPHEN : 325 MG METHOCARBAMOL : 400 MG |
| Manufacturer | VITA HEALTH PRODUCTS INC |
| Strength | 325 MG |
| Dosage form | TABLET |
| Route of administration | ORAL |
| Schedule | NON-PRESCRIPTION DRUGS |
| ATC code | M03BA53 METHOCARBAMOL, COMBINATIONS EXCL PSYCHOLEPTICS |
| AHFS class | 38:00.00 |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 17-Oct-2001 |
| Original market date | 1997-04-15 00:00:00 |
What can be used instead?
Other Canadian products sharing ATC code M03BA53 METHOCARBAMOL, COMBINATIONS EXCL PSYCHOLEPTICS. 13 of 68 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| EXTRA STRENGTH MUSCLE & BACK PAIN ASA 500 MG METHOCARBAMOL 400 MG & ACETYLSALICYLIC ACID 500 MG | 400 MG | TABLET | VITA HEALTH PRODUCTS INC | MARKETED | DIN 02252228 |
| EXTRA STRENGTH MUSCLE & BACK PAIN RELIEF | 500 MG | TABLET | VITA HEALTH PRODUCTS INC | MARKETED | DIN 02239141 |
| EXTRA STRENGTH MUSCLE & BACK PAIN RELIEF WITH ASA | 500 MG | TABLET | VITA HEALTH PRODUCTS INC | MARKETED | DIN 02426625 |
| EXTRA STRENGTH TYLENOL BACK PAIN | 400 MG | TABLET | MCNEIL CONSUMER HEALTHCARE DIVISION OF JOHNSON & JOHNSON INC | MARKETED | DIN 02290510 |
| EXTRA STRENGTH TYLENOL BODY PAIN NIGHT | 500 MG | TABLET | MCNEIL CONSUMER HEALTHCARE DIVISION OF JOHNSON & JOHNSON INC | MARKETED | DIN 02357356 |
| MOTRIN PLATINUM MUSCLE & BODY | 200 MG | TABLET | MCNEIL CONSUMER HEALTHCARE DIVISION OF JOHNSON & JOHNSON INC | MARKETED | DIN 02418967 |
| MUSCLE AND BACK PAIN PLATINUM RELIEF | 200 MG | TABLET | VITA HEALTH PRODUCTS INC | MARKETED | DIN 02422042 |
| MUSCLE AND BACK PAIN RELIEF | 500 MG | TABLET | VITA HEALTH PRODUCTS INC | MARKETED | DIN 02451298 |
| ROBAX PLATINUM | 500 MG | TABLET | HALEON CANADA ULC | MARKETED | DIN 02247147 |
| ROBAXACET | 325 MG | TABLET | HALEON CANADA ULC | MARKETED | DIN 02026805 |
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.